The Clinical Research Office (CRO) provides central management and oversight functions for coordinating, facilitating and reporting on phase l-lll clinical trials, pilot studies and population-based studies of the Cancer Center with an emphasis on institutional trials. CRO services include: protocol development and maintenance support;regulatory support;data systems management;quality control;operational support; and information systems. With centralized services, the CRO provides a stable and efficient administrative structure to coordinate these activities across the entire scope of the Mayo Clinic Cancer Center (MCCC). This service is available to all MCCC investigators regardless of Mayo campus. The CRO supports clinical trials and non-interventional population-based clinical research that are supported by one or more of the following: ? Peer-reviewed extramural funds (NIH, DOD, etc.), ? Mayo Clinic Cancer Center (including CCSG) ? Phase I and Phase II (NCI, U01, N01) ? Chemoprevention Network (CPN) ? NCI Cooperative Group and CCOP Programs [MCCC is the research base of the North Central Cancer Treatment Group (NCCTG), serves as the Statistics and Data Center for the ACOSOG and is a member of ACOSOG, COG, ECOG, GOG, NCCTG and RTOG] ? Industry funds The ability to use the same remote registration system, remote data entry system and database for all studies and to configure tables, interfaces and reports to meet program and protocol specific needs allows systems and procedures to be consistent between all sponsors and programs and ensures compliance with regulatory requirements. This consistency fosters efficiency and programmatic operational synergy while leveraging expertise across different NCI mechanisms of clinical trial support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-39
Application #
8465667
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
39
Fiscal Year
2013
Total Cost
$437,135
Indirect Cost
$134,510
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Li, Mulin Jun; Li, Miaoxin; Liu, Zipeng et al. (2017) cepip: context-dependent epigenomic weighting for prioritization of regulatory variants and disease-associated genes. Genome Biol 18:52
Paulus, A; Akhtar, S; Yousaf, H et al. (2017) Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J 7:e565
Patnaik, Mrinal M; Barraco, Daniela; Lasho, Terra L et al. (2017) Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol 92:542-548
Finnes, Heidi D; Chaffee, Kari G; Call, Timothy G et al. (2017) Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma 58:1376-1383
Russell, Stephen J; Peng, Kah-Whye (2017) Oncolytic Virotherapy: A Contest between Apples and Oranges. Mol Ther 25:1107-1116
Pathangey, Latha B; McCurry, Dustin B; Gendler, Sandra J et al. (2017) Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. Oncotarget 8:10785-10808
Peacock, Justin G; Harmsen, William S; Link, Michael J et al. (2017) Risk of Delayed Lymph Node Metastasis in Clinically N0 Esthesioneuroblastoma. J Neurol Surg B Skull Base 78:68-74
Ertz-Archambault, Natalie; Kosiorek, Heidi; Taylor, Gretchen E et al. (2017) Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncol 3:936-943
Zhou, Dan; Hlady, Ryan A; Schafer, Marissa J et al. (2017) High fat diet and exercise lead to a disrupted and pathogenic DNA methylome in mouse liver. Epigenetics 12:55-69
Miyoshi, Jinsei; Toden, Shusuke; Yoshida, Kazuhiro et al. (2017) MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep 7:43393

Showing the most recent 10 out of 1086 publications